PH12020551185A1 - Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation - Google Patents

Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Info

Publication number
PH12020551185A1
PH12020551185A1 PH12020551185A PH12020551185A PH12020551185A1 PH 12020551185 A1 PH12020551185 A1 PH 12020551185A1 PH 12020551185 A PH12020551185 A PH 12020551185A PH 12020551185 A PH12020551185 A PH 12020551185A PH 12020551185 A1 PH12020551185 A1 PH 12020551185A1
Authority
PH
Philippines
Prior art keywords
atopic dermatitis
treatment
nemolizumab
excoriation
moderate
Prior art date
Application number
PH12020551185A
Other languages
English (en)
Inventor
Nabil Kerrouche
Keiko Hirokawa
Ryosuke Mihara
Original Assignee
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65729402&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12020551185(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Holding SA, Chugai Pharmaceutical Co Ltd filed Critical Galderma Holding SA
Publication of PH12020551185A1 publication Critical patent/PH12020551185A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PH12020551185A 2018-02-09 2020-08-05 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation PH12020551185A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09
PCT/IB2019/051051 WO2019155427A1 (en) 2018-02-09 2019-02-08 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Publications (1)

Publication Number Publication Date
PH12020551185A1 true PH12020551185A1 (en) 2021-05-17

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551185A PH12020551185A1 (en) 2018-02-09 2020-08-05 Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Country Status (23)

Country Link
US (2) US12435147B2 (cg-RX-API-DMAC7.html)
EP (2) EP4644424A3 (cg-RX-API-DMAC7.html)
JP (3) JP7777921B2 (cg-RX-API-DMAC7.html)
CN (1) CN112040976A (cg-RX-API-DMAC7.html)
AU (2) AU2019219608B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016144A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090062A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002050A1 (cg-RX-API-DMAC7.html)
DK (1) DK3749353T3 (cg-RX-API-DMAC7.html)
ES (1) ES3049513T3 (cg-RX-API-DMAC7.html)
FI (1) FI3749353T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251101T1 (cg-RX-API-DMAC7.html)
IL (1) IL276524A (cg-RX-API-DMAC7.html)
LT (1) LT3749353T (cg-RX-API-DMAC7.html)
MX (1) MX2020008193A (cg-RX-API-DMAC7.html)
PH (1) PH12020551185A1 (cg-RX-API-DMAC7.html)
PL (1) PL3749353T3 (cg-RX-API-DMAC7.html)
PT (1) PT3749353T (cg-RX-API-DMAC7.html)
RU (1) RU2758378C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007558YA (cg-RX-API-DMAC7.html)
SI (1) SI3749353T1 (cg-RX-API-DMAC7.html)
TW (2) TWI856006B (cg-RX-API-DMAC7.html)
WO (1) WO2019155427A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535464A (zh) * 2023-11-02 2025-09-16 日商丸寶股份有限公司 醫藥組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
FI3284480T3 (fi) * 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2017093857A1 (en) * 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
IL276524A (en) 2020-09-30
JP2023182632A (ja) 2023-12-26
EP4644424A3 (en) 2026-01-14
TW202448919A (zh) 2024-12-16
WO2019155427A1 (en) 2019-08-15
CL2020002050A1 (es) 2020-12-11
RU2758378C1 (ru) 2021-10-28
CA3090062A1 (en) 2019-08-15
TWI856006B (zh) 2024-09-21
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
HRP20251101T1 (hr) 2025-11-21
JP7777921B2 (ja) 2025-12-01
US20200385476A1 (en) 2020-12-10
SI3749353T1 (sl) 2025-10-30
EP3749353B1 (en) 2025-07-30
TWI923998B (zh) 2026-05-01
JP2025176134A (ja) 2025-12-03
AU2019219608B2 (en) 2025-10-16
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
EP4644424A2 (en) 2025-11-05
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
TW201941800A (zh) 2019-11-01
JP2021512917A (ja) 2021-05-20
US20260008859A1 (en) 2026-01-08
SG11202007558YA (en) 2020-09-29
PL3749353T3 (pl) 2025-12-08
ES3049513T3 (en) 2025-12-17
DK3749353T3 (da) 2025-09-01
FI3749353T3 (fi) 2025-09-10
BR112020016144A2 (pt) 2020-12-15
PT3749353T (pt) 2025-10-14
CN112040976A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
MX2022004259A (es) Inhibidores de mek para el tratamiento de infecciones por hantavirus.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12020551427A1 (en) Epinephrine spray formulations
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX2017014020A (es) Terapia antimicrobiana.
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
SA519410324B1 (ar) صياغات رش إيبينيفرين
PH12019550265B1 (en) Composition comprising mannose oligosaccharide and process for making same and use thereof
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
EP4640237A3 (en) Macrophage-based therapy for use in the treatment of acute liver injury
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
EP4644424A3 (en) Treatment of atopic dermatitis with moderate to severe excoriation
WO2020032902A3 (en) Aksolotl blastema for use in the treatment of wounds and burns